Skip to main content
. 2023 Feb 13;120(8):e2211703120. doi: 10.1073/pnas.2211703120

Fig. 3.

Fig. 3.

rSEA immunotherapy promotes repair in articular joint injuries. (A) ACLT injury model timeline. (B) Representative images from safranin-O stains of uninjured joints (no surgery) or injured joints treated with vehicle or rSEA 4 wk post-ACLT. Arrows indicate where cartilage damage has occurred. (C) OARSI scoring of uninjured joints or injured joints treated with vehicle or rSEA 4 wk post-ACLT. (D), Articular joint gene expression of type 2, type 3 immune genes, and cartilage ECM genes Aggrecan (Acan), type 2 collagen (Col2a1), and Lubricin (Prg4) 4 wk post-ACLT treated with vehicle or rSEA. (E) iLN gene expression of type 2 and type 3 immune genes 4 wk post-ACLT. (F) Hot plate reaction times and weight-bearing assessments in mice without injury or 4 wk post-ACLT treated with vehicle (saline) or rSEA. Statistical tests represent all biological replicates, and all experiments were replicated at least twice. Graphs show mean ± SD (C–E), n = 4 to 5, box and whisker plot with median as central line, and “+” designates mean (C). *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 by one-way ANOVA with Tukey’s multiple comparisons (C and F) and two-way ANOVA with Sidak’s multiple comparisons (D and E). (Scale bar, 100 μm (B).)